To prevent muscle loss, more physicians are emphasizing the importance of fat loss vs weight loss for patients taking GLP-1 ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Continuing GLP-1 RA use through surgery increases risk for surgical complications including aspiration and conversion to intubation ...

Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications. HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially developed to regulate blood glucose levels in patients with type 2 diabetes mellitus (T2DM). However, their therapeutic effects ...